Société de Chimie Industrielle’s Post

Our discussions with industry leaders at the American Chemical Council's (ACC) Annual Meeting centered around 5 key themes: 1. The sentiment of the conference was cautious optimism, reflecting volume recovery and continuing price normalization 🔮 2. Geopolitical uncertainty is limiting decisive investments – Players are making agile and pragmatic no regret moves ⚖ 3. The chemicals sector in Europe is at a crossroads – Either government support will bolster the industry, or it will be forced to shrink 💶 4. Capacity increases in China have driven industry overcapacity and challenge global economics 🌏 5. The US is an investment opportunity due to its advantaged feedstock economics and public sector support 💵 How do these themes resonate with your business? Let's discuss. Rob Henske Jonathon Wright Danny Mueller Erwin Douma Rett Johnson Doug Bade Ruirui Zong-Rühe Peter Odenwälder Alexander Baumgartner Mathieu Rasamoela Brag Selvarajan Bradley McMullin, CFA Christian Lumpe Khyati Jain Katherine Bartels, MBA Dilhani De Silva Frank Steffen

Dive into 3 unintended consequences of the Inflation Reduction Act thats you probably have not heard of yet, today on Dr. White’s Biotech Renaissance Vlog! Our brains crave context and connections. Each week, we will explore major developments in biotech to help you navigate the evolving industry, landscape, identify, emerging opportunities, and support your professional growth. Share your insights and feedback, as well as any suggestions for future topics!

Hear from our experts. #swissmen #expertnetwork #experts #research #insights

Factor investing: Factors are to assets what nutrients are to food portfolio institutional is holding a roundtable on factor investing on November 6 from 2-5pm in central London which will be open to audience members. The roundtable will explore a number of key themes: What do we mean by factor investing? How has factor investing evolved? How are institutional investors utilising factors? What are the benefits? What are the risks? Following the discussion, audience members will have the opportunity to engage in a Q&A session with the panelists. The event will conclude with a post-event networking session, providing a platform for further discussions and connections. Go here to register your interest to attend. https://lnkd.in/epUbp2mE

My cofounder, Dr. Bradley, has been involved in nearly every major clinical trial in the last 20 years...it's part of what makes our drug alternatives so special. GLP1's aren't the first drugs to have many indications and interesting clinical trial results. Check out his thoughts in this insightful article from the field! #glp1 #pharmacycost #drugprices #hrinnovation

Mike McKenna, North America CEO at Barentz, shared his vision on the company's strategic focus and market trends in his recent interview with ICIS TOP 100 Chemical Distributors edition: "We have a lot of opportunities to expand out market share in different geographies and in different market segments, and that’s what our team is focused on”. In the interview, Mike highlights our commitment to innovation and customer-centric strategies, emphasizing the importance of adapting to market demands and leveraging regional strengths. He also discussed the challenges and opportunities in the current economic climate, particularly in light of recent global supply chain disruptions and energy cost fluctuations. Read the full interview here: https://lnkd.in/eYwWZTk4

Economic evaluations are instrumental for life science manufacturers, offering crucial insights into market access, shaping competitive pricing strategies, and informing strategic decision-making pathways. Learn more in our latest thought leadership article by Carelon Research’s Emma Richard. https://bit.ly/4cKcg1k #economicevaluations

💸 The funding environment for alternative proteins has shifted dramatically—but paths forward are emerging. For companies ready to commercialize, funding remains constrained, inspiring creative, multi-pronged strategies to accessing capital. Through extensive research and cross-industry interviews, our corporate engagement team has developed a financing guide for alternative protein companies navigating this challenging funding environment. Sharyn Murray, CFA 🔸, our senior manager of investor engagement and financing, explores the key insights from this guide in a new blog 👉 https://bit.ly/4emyZAf Want to dig deeper? Check out our recent webinar, The Business of Alt Protein: Financing alternative protein commercialization, here 👉 https://bit.ly/4eGrl3X

Hear from our Head of Life Sciences & Alternatives, Capital Markets, Alistair Meadows as he discusses investor appetite for the life sciences sector. Discover more in our latest report '2024 EMEA Life Sciences Industry & Real Estate Perspective' by following the link below ⬇️ #lifesciences #capitalmarkets #investor

Our recent Socrates Seminar on "The Future of Business" brought together 21 influential participants from sectors including agriculture, tourism, pharmaceuticals, energy, and finance. This event served as a vital platform for thought-provoking discussions and strategic foresight. One participant shared, "The extensive readings and guided dialogues were an exceptional way to explore ideas and build a shared understanding of key issues shaping our world of business. It was incredibly stimulating to hear the diverse stories and shared commitment to using the power of business to make the world a better place." Find a full summary of the seminar here: https://lnkd.in/gJkfu8n9